Chinese maker of insulin and insulin analogs, competing with multinational diabetes-drug makers domestically and via partners abroad.
Chinese maker of insulin and insulin analogs, competing with multinational diabetes-drug makers domestically and via partners abroad.
Sells insulin to Chinese hospitals mainly through government volume-based tenders, which trade lower prices for guaranteed volumes. Outside China it licenses products to partners, including Sandoz, that run approvals and sales in their markets. Newer candidates in the GLP-1 class, used for diabetes and weight loss, are in development.
In one line: China's Novo Nordisk for insulin.
Moat: narrow (scale, process know-how, regulatory licence). One of few Chinese makers with FDA-relevant insulin manufacturing and international partnerships.
Headquarters: Beijing, China · Founded: 1998 · Employees: 5,309
Size Gan & Lee Pharmaceuticals (603087.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $5.59B, the 420th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥62.53 on 18 Nov 2026.
Performance Over six months the shares gained 10.6%, against -6.5% for the median peer and -20.0% for the China market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue grew 14.2% over the last twelve months (peer median +14.2%); the operating margin is 20.3% (peer median 18.4%).
Valuation It trades at 25.8× forward earnings against a peer median of 22.6× (8th most expensive of 17).
Capital Return on invested capital runs 2.6 points above its cost of capital (8.3% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥4.37B | CN¥4.04B | CN¥3.01B | CN¥2.60B | CN¥1.71B |
| Revenue growth | — | +34% | +16% | +52% | — |
| Gross profit | CN¥3.45B | CN¥2.94B | CN¥2.13B | CN¥1.80B | CN¥1.20B |
| EBITDA | n/a | CN¥1.07B | CN¥555M | CN¥407M | -CN¥474M |
| Net income | CN¥1.18B | CN¥1.14B | CN¥615M | CN¥340M | -CN¥440M |
| Free cash flow | -CN¥159M | -CN¥49.2M | CN¥185M | -CN¥125M | -CN¥505M |
| Capital expenditure | CN¥1.33B | CN¥926M | CN¥441M | CN¥553M | CN¥983M |
| Total debt | CN¥235M | CN¥121M | CN¥200M | CN¥79.0M | CN¥85.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Gan & Lee Pharmaceuticals 603087.SS | $5.59B | +11% | +14% | 20% | 25.8× | n/a |
| Novo Nordisk A/S NOVO-B.CO | $177B | -6% | +6% | 48% | 11.8× | -0.5% |
| Lilly (Eli) LLY | $1.30T | +36% | +46% | 51% | 29.5× | 6.5% |
| Tonghua Dongbao Pharmaceutical 600867.SS | $2.19B | -12% | +18% | n/a | 25.4× | 0.9% |
| Sanofi SAN.PA | $114B | +13% | +15% | 27% | 9.7× | -4.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603087.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.8% | -0.3% | 2nd lowest of 21 |
| 6-month return | +10.6% | -6.5% | 8th highest of 21 |
| Distance from 52-week high | -21.8% | -31.1% | 8th highest of 21 |
| Revenue growth (TTM) | +14.2% | +14.2% | 9th highest of 17 |
| Operating margin | 20.3% | 18.4% | 9th highest of 18 |
| Forward P/E | 25.8× | 22.6× | 8th most expensive of 17 |
| ROIC minus cost of capital | +2.6 pp | +1.5 pp | 8th highest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Gan & Lee Pharmaceuticals 603087.SS | China | $5.59B | +11% | +14% | 20% | 25.8× | n/a | n/a |
| Gland Pharma GLAND.NS | India | $5.71B | +44% | +22% | 21% | 39.3× | 20.2% | +13.3% |
| Abbott India ABBOTINDIA.NS | India | $5.80B | -8% | +7% | 28% | 31.1× | 8.0% | +10.0% |
| Sumitomo Pharma 4506.T | Japan | $5.33B | +11% | +11% | 10% | 8.6× | 1.7% | -2.6% |
| Shanghai Allist Pharmaceuticals 688578.SS | China | $5.32B | -14% | +39% | 47% | 12.4× | 0.1% | +519.6% |
| Veradermics MANE | United States | $5.27B | +19% | n/a | n/a | n/a | n/a | n/a |
| Ligand Pharmaceuticals LGND | United States | $5.98B | +37% | +1% | 14% | 27.3× | 57.7% | +7.5% |
| Supernus Pharmaceuticals SUPN | United States | $6.02B | -41% | +16% | 45% | 8.0× | 6.2% | +13.9% |
| Mirum Pharmaceuticals MIRM | United States | $6.04B | -5% | +42% | -21% | n/a | n/a | n/a |
| RemeGen 9995.HK | Hong Kong | $6.07B | -28% | +293% | 61% | 6.3× | -6.8% | +57.9% |
| Liquidia LQDA | United States | $5.08B | -9% | +798% | 47% | 13.8× | 5.0% | +192.5% |
| SKBP 326030.KS | South Korea | $5.03B | -16% | +37% | 38% | 21.5× | -4.4% | +93.6% |
| PTC Therapeutics PTCT | United States | $5.03B | -15% | -35% | 22% | 31.2× | 6.6% | +35.4% |
| IPCA Laboratories IPCALAB.NS | India | $5.03B | +12% | +12% | 18% | 31.1× | 16.5% | +12.2% |
| Biocon BIOCON.NS | India | $6.31B | -15% | +6% | 8% | 61.3× | n/a | n/a |
| Beijing TongRenTang 600085.SS | China | $4.91B | -12% | -17% | 8% | 28.7× | 1.7% | +6.2% |
| Belite Bio, Inc. ADR BLTE | United States | $6.41B | +9% | n/a | n/a | n/a | n/a | n/a |
| Humanwell Healthcare (Group) 600079.SS | China | $4.87B | +11% | +2% | 15% | 13.8× | -8.8% | +3.0% |
| Erasca ERAS | United States | $4.83B | +24% | n/a | n/a | n/a | n/a | n/a |
| Travere Therapeutics TVTX | United States | $4.82B | +16% | +49% | -3% | 17.1× | 17.3% | +19.9% |
| Samsung Epis 0126Z0.KS | South Korea | $6.49B | -31% | n/a | 12% | 23.8× | n/a | n/a |